拉莫三嗪与拉考沙胺在胶质瘤癫痫患者中的疗效比较
本研究为多中心回顾性分析,纳入139例弥漫性2-4级胶质瘤伴癫痫发作患者,比较拉莫三嗪与拉考沙胺在左乙拉西坦或丙戊酸一线单药治疗失败后的疗效。主要终点为治疗失败的累积发生率,以死亡为竞争事件。结果显示两种药物12个月治疗失败率无显著差异。
要点
- 拉莫三嗪与拉考沙胺在胶质瘤癫痫患者中疗效相似。
- 12个月治疗失败率:拉莫三嗪38%,拉考沙胺30%,无统计学差异。
- 因癫痫未控制或不良事件导致的治疗失败率两组无显著差异。
核心结论
- 拉莫三嗪与拉考沙胺在弥漫性胶质瘤伴癫痫患者中显示出相似的疗效。
研究设计与样本
- 多中心回顾性研究,纳入139例弥漫性2-4级胶质瘤伴癫痫发作患者,均在一线单药治疗(左乙拉西坦或丙戊酸)失败后接受拉莫三嗪或拉考沙胺治疗。
主要发现
- 12个月任何原因治疗失败的累积发生率:拉莫三嗪38%(95%CI 26-51%),拉考沙胺30%(95%CI 20-41%),无统计学显著差异。
- 拉考沙胺相比拉莫三嗪的治疗失败调整风险比为0.84(95%CI 0.46-1.56)。
- 因癫痫未控制导致的治疗失败累积发生率:拉莫三嗪18% vs 拉考沙胺11%,无显著差异。
- 因不良事件导致的治疗失败累积发生率:拉莫三嗪17% vs 拉考沙胺19%,无显著差异。
临床怎么用
- 在胶质瘤相关癫痫患者中,拉莫三嗪和拉考沙胺均可作为一线单药治疗失败后的选择,两者疗效相当。
局限性
- 回顾性研究设计可能引入选择偏倚,样本量有限(139例),需前瞻性研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Optimal treatment with antiepileptic drugs (AEDs) is an important part of care for brain tumor patients with epileptic seizures. Lamotrigine and lacosamide are both examples of frequently used non-enzyme inducing AEDs with limited to no drug-drug interactions, reducing the risk of unfavorable side effects. This study aimed to compare the effectiveness of lamotrigine versus lacosamide. METHODS: In this multicenter study we retrospectively analyzed data of patients with diffuse grade 2-4 glioma with epileptic seizures. All patients received either lamotrigine or lacosamide during the course of their disease after treatment failure of first-line monotherapy with levetiracetam or valproic acid. Primary outcome was the cumulative incidence of treatment failure, from initiation of lamotrigine or lacosamide, with death as competing event, for which a competing risk model was used. Secondary outcomes were uncontrolled seizures after AED initiation and level of toxicity. RESULTS: We included a total of 139 patients of whom 61 (44%) used lamotrigine and 78 (56%) used lacosamide. At 12 months, there was no statistically significant difference in the cumulative incidence of treatment failure for any reason between lamotrigine and lacosamide: 38% (95%CI 26-51%) versus 30% (95%CI 20-41%), respectively. The adjusted hazard ratio for treatment failure of lacosamide compared to lamotrigine was 0.84 (95%CI 0.46-1.56). The cumulative incidences of treatment failure due to uncontrolled seizures (18% versus 11%) and due to adverse events (17% versus 19%) did not differ significantly between lamotrigine and lacosamide. CONCLUSION: Lamotrigine and lacosamide show similar effectiveness in diffuse glioma patients with epilepsy.
引用
- van Opijnen MP, van der Meer PB, Dirven L, et al. The effectiveness of antiepileptic drug treatment in glioma patients: lamotrigine versus lacosamide. J Neurooncol. 2021. PMID: 34196916. doi:10.1007/s11060-021-03800-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。